Novo Nordisk Stock Performance
as on November 5, 2026 at 6:10 am IST
Day's Low
Day's High
$42.13$43.23
1.50%
Downside
1.08%
Upside
52 Week's Low
52 Week's High
$35.12$64.1617.89%
Downside
50.01%
Upside
Novo Nordisk share price movements today
- Previous Close
- $40.19
- Open
- $42.45
- Volume
- 13.8M
- Market Cap
- $176.3B
- Dividend Yield
- 4.49%
- Day's Low - High
- $42.13 - $43.23
- 52 Week Low - High
- $35.12 - $64.16
Novo Nordisk Historical Returns
- 1 Month Return
- + 8.39 %
- 3 Month Return
- -14.1 %
- 1 Year Return
- -17.63 %
- 3 Year Return
- -58.8 %
- 5 Year Return
- -29.99 %
Novo Nordisk Stock Fundamentals & Key Indicators
Check Novo Nordisk market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$176.3B
EPS (TTM)
26.23
Dividend Yield
4.49%
Quarterly Earnings Growth YOY
-0.21%
PE Ratio (TTM)
10.15
Industry PE ratio
9.91
PEG Ratio
2.03
EBITDA
180.9B
Revenue (TTM)
329.4B
Profit Margin
80.65%
Return On Equity TTM
59.09%
Novo Nordisk vs Peer Comparison
Compare market cap, revenue, PE, and other key metrics of Novo Nordisk with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % | Dividend Yield % |
|---|---|---|---|---|---|---|
| Neutral | $176.3B | -29.99% | 10.15 | 80.65% | 4.49% | |
| StrongBuy | $1.3T | 429.93% | 45.89 | 83.63% | 0.47% | |
| StrongBuy | $521.1B | 145.67% | 50.58 | 76.25% | 2.35% | |
| Buy | $657.7B | 63.92% | 41.42 | 68.81% | 1.93% | |
| StrongBuy | $289.9B | 46.15% | 26.26 | 77.59% | 1.73% |
Stock Returns calculator for Novo Nordisk Stock including INR - Dollar returns
The Novo Nordisk stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.
Investment Value
₹1,00,000
Novo Nordisk investment value today
Current value as on today
₹92,889
Returns
Returns from Novo Nordisk Stock
Dollar Impact
₹5,799 (+5.8%)
Analyst Recommendation on Novo Nordisk Stock
Based on 4 analysts
0.00%
Buy
75.00%
Hold
25.00%
Sell
Based on 4 analysts, 75% of analysts recommend a 'HOLD' rating for Novo Nordisk. Average target price of $44.97
Novo Nordisk Share Price Target
Get share price movements and forecasts by analysts on Novo Nordisk.
What analysts predicted
4.89%UPSIDE
Target Price
$44.97
Current Price
$42.77
Analyzed by
4 Analysts
High
$47
Target
$44.97
Low
$40
Novo Nordisk target price $44.97, a slight upside of 4.89% compared to current price of $42.77. According to 4 analysts rating.
Indian Investors' Interest in Novo Nordisk Stock
Investment in Novo Nordisk Shares on INDmoney has grown by 77.63% in the last 30 days, indicating increased investment activity.
Time period: to
Change:77.63% versus previous 30 day period
Search interest for Novo Nordisk Stock has decreased by -44% in the last 30 days, reflecting a downward trend in search activity.
Time period: to
Novo Nordisk Quarterly Profit & Loss
All numbers in Millions USD
Novo Nordisk Annual Profit & Loss
All numbers in Millions USD
Novo Nordisk Quarterly Cash Flow
All numbers in Millions USD
Novo Nordisk Annual Cash Flow
All numbers in Millions USD
Novo Nordisk News & Key Events
Today's Timeline - 04 November
Wed, 12:50 PM
-Novo Nordisk raises 2026 sales outlook after strong Q3 performance driven by obesity treatment demand.
Wed, 04:58 PM
-Shares jump 5% after stronger-than-expected Q3 results and raised full-year outlook for GLP-1 drug sales.
Wed, 07:10 PM
-Novo shares rise 5.28% in premarket after reporting Q3 earnings of $0.89 per share, beating estimates.
Today's Timeline - 04 November
Wed, 08:39 PM
-Novo reports Q3 earnings, shares climb 4.1% over the week, but still below earlier levels.
Wed, 11:16 PM
-Shares gained over 6% after earnings beat expectations, raising fiscal 2026 outlook due to GLP-1 product sales.
Insights on Novo Nordisk
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTPrice Rise
In the last 7 days, NVO stock has moved up by 5.0%
NO EFFECTAgainst Peers
In the last 3 years, Eli Lilly & Co. has given 39.9% return, outperforming this stock by 99.0%
- NO EFFECT
Against Peers
In the last 1 year, Merck & Co., Inc. has given 72.5% return, outperforming this stock by 89.2%
NEGATIVE IMPACTProfit Down
Novo-Nordisk A/S has experienced a decline in net profit over the past two quarters. The net profit decreased from $48.55 billion to $20.98 billion, resulting in an average decrease of 56.8% per quarter.
- NEGATIVE IMPACT
Revenue Fall
Novo-Nordisk A/S has experienced a decline in revenue over the last two quarters. The revenue decreased from $96.82 billion to $78.48 billion, averaging a decrease of 18.9% each quarter.
About Novo Nordisk
Novo Nordisk is a pharmaceutical company that develops, manufactures and markets medicines for diabetes, obesity and selected rare diseases. Its portfolio includes insulin, GLP-1-based medicines and treatments for blood and endocrine disorders.
Its principal reporting segments are Diabetes and Obesity Care and Rare Disease. Brands include Ozempic, Rybelsus and Wegovy, alongside its insulin and rare disease products. The company combines drug research and clinical development with regulated manufacturing and distribution through healthcare supply chains.
How Does Novo Nordisk Make Money?
Novo Nordisk makes money primarily by selling medicines. Its recognised sales reflect the commercial terms of supplying those products, including applicable discounts, rebates, returns and other adjustments.
| Business area and customer need | What Novo Nordisk provides | How Novo Nordisk earns revenue |
|---|---|---|
| Diabetes and Obesity Care-Diabetes GLP-1: Supply prescribed diabetes treatments | Products including Ozempic and Rybelsus | Net sales of medicines through healthcare distribution channels |
| Diabetes and Obesity Care-Obesity: Supply approved weight-management treatments | Wegovy and related obesity care products | Net medicine sales |
| Diabetes and Obesity Care-Insulin and related products: Supply established diabetes therapies | Insulins and other relevant products | Sales to wholesalers, distributors and other eligible customers |
| Rare Disease: Treat selected blood and endocrine disorders | Rare disease medicines | Net pharmaceutical sales |
Product rows within Diabetes and Obesity Care are therapeutic areas, not separate financial reporting segments.
Who pays through the medicine supply chain
Medicines can move through wholesalers, distributors, pharmacies and healthcare institutions, with insurers or public systems also influencing payment and access. The patient's out-of-pocket bill is therefore not necessarily the revenue Novo Nordisk receives. Its sales reflect its own supply arrangements and applicable deductions.
Why list price differs from net sales
A published medicine price can be adjusted by negotiated discounts, rebates and other commercial terms. Manufacturing and distribution volumes also matter. Understanding the business requires distinguishing the amount of medicine supplied from the net price the company actually earns on that supply.
Where repeat revenue comes from
Ongoing prescribed treatment can support repeat demand, while access to additional patients and markets can create further sales. Revenue depends on approvals, availability, prescribing, reimbursement and actual product supply. Drug development provides future opportunities, while established revenue comes from commercial products and services that have reached paying customers.
| Organisation | Novo Nordisk |
| Headquarters | Novo Alle 1, Bagsvaerd, CR, 2880, DK |
| Industry | Drug Manufacturers - General |
| CEO | Maziar Mike Doustdar |
Key Management of Novo Nordisk
Name | Title |
|---|---|
Mr. Karsten Munk Knudsen | Executive VP, CFO & Member of the Management Board |
Dr. Martin Holst Lange | EVP of R&D, Chief Scientific Officer and Member of the Management Board |
Ms. Thilde Hummel Bogebjerg | Executive VP of Enterprise IT & Quality and Member of Management Board |
Mr. Emil Kongshoej Larsen | EVP of International Operations & Member of Management Board |
Mr. Jamey Millar | Executive VP of US Operations & Member of Management Board |
Ms. Hong Chow | Executive VP of Product & Portfolio Strategy and Member of Management Board |
Mr. Maziar Mike Doustdar B.A. | President, CEO & Member of the Management Board |
Ms. Tania Sabroe | EVP of People, Organisation and Corporate Affairs & Member of Management Board |
Mr. John F. Kuckelman | SVP, Group General Counsel, Global Legal, IP & Security and Member of Management Board |
Ms. Elin Jager | SVP, Chief of Staff to CEO, Corporate Strategy & Sustainability and Member of Management Board |
FAQs
What is Novo Nordisk share price today?
Novo Nordisk share price today is $42.77 as on . Novo Nordisk share today touched a day high of $43.23 and a low of $42.13.
What is the 52 week high and 52 week low for Novo Nordisk share?
Novo Nordisk share touched a 52 week high of $64.16 on and a 52 week low of $35.12 on . Novo Nordisk stock price today i.e. is trending at $42.77,which is 33.34% down from its 52 week high and 21.78% up from its 52 week low.
What is Novo Nordisk's market capitalisation today?
Novo Nordisk market capitalisation is $0.18T as on .
How to invest in Novo Nordisk Stock (NVO) from India?
- Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
- Step 2: Search for Novo Nordisk on INDmoney app. Click on Buy button.
What is the minimum amount required to buy Novo Nordisk Stock (NVO) from India?
Indian investors can start investing in Novo Nordisk (NVO) shares with as little as ₹94.63999938964844 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹946.40 in Novo Nordisk stock (as per the Rupee-Dollar exchange rate as on ).
Based on Novo Nordisk share’s latest price of $42.77 as on November 5, 2026 at 12:40 am IST, you will get 0.2338 shares of Novo Nordisk. Learn more about
fractional shares .
What are the returns that Novo Nordisk has given to Indian investors in the last 5 years?
Novo Nordisk stock has given -29.99% share price returns and 27.31% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?